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Amniotic fluid holds great promise as a stem cell source, especially in neonatal applications where autologous
cells can be isolated and used. This study examined chemical-mediated differentiation of amniotic fluid-derived
stem cells (AFSC) into endothelial cells and verified the function of AFSC-derived endothelial cells (AFSC-EC).
AFSC were isolated from amniotic fluid obtained from second trimester amnioreduction as part of therapeutic
intervention from pregnancies affected with twin-twin transfusion syndrome. Undifferentiated AFSC were of
normal karyotype with a subpopulation of cells positive for the embryonic stem cell marker SSEA4, hemato-
poietic stem cell marker c-kit, and mesenchymal stem cell markers CD29, CD44, CD73, CD90, and CD105.
Additionally, these cells were negative for the endothelial marker CD31 and hematopoietic differentiation
marker CD45. AFSC were cultured in endothelial growth media with concentrations of vascular endothelial
growth factor (VEGF) ranging from 1 to 100 ng/mL. After 2 weeks, AFSC-EC expressed von Willebrand factor,
endothelial nitric oxide synthase, CD31, VE-cadherin, and VEGF receptor 2. Additionally, the percentage of cells
expressing CD31 was positively correlated with VEGF concentration up to 50 ng/mL, with no increase at higher
concentrations. AFSC-EC showed a decrease in stem cells markers c-kit and SSEA4 and were morphologically
similar to human umbilical vein endothelial cells (HUVEC). In functional assays, AFSC-EC formed networks and
metabolized acetylated low-density lipoprotein, also characteristic of HUVEC. Nitrate levels for AFSC-EC, an
indirect measure of nitric oxide synthesis, were significantly higher than undifferentiated controls and signifi-
cantly lower than HUVEC. These results indicate that AFSC can differentiate into functional endothelial-like cells
and may have the potential to provide vascularization for constructs used in regenerative medicine strategies.
Introduction
Human amniotic fluid-derived stem cells (AFSC)offer distinct advantages for use in the field of regen-
erative medicine when compared with other stem and pro-
genitor cell types. AFSC have been shown to express markers
characteristic of both embryonic stem cells (ESC) and mes-
enchymal stem cells (MSC)1,2 and have the ability to differ-
entiate across all three germ layers, including cardiovascular
lineages,2–4 while maintaining the nontumor forming prop-
erties of adult stem cells.5,6 Additionally, AFSC are capable
of maintaining prolonged undifferentiated proliferation at
rates similar to ESC.2,7
AFSC lack a unique surface antigen that can be used for
positive selection; one strategy for the enrichment of AFSC is
based on the adherence of cells to plastic dishes within 24 to
48 h.1,8 This subpopulation can be further enriched by im-
munological selection based on expression of the membrane
receptor c-kit, which is present in 1.0% to 5.0% of total cells in
amniotic fluid (AF) and placenta.1,2,7 In bone marrow-
derived MSC, c-kit+ selection has been shown to be a marker
of cardiovascular progenitor cells and also serves to remove
mature cells from the adherent population.9 The use of
growth factors, such as vascular endothelial growth factor
(VEGF), to induce chemical-mediated endothelial differenti-
ation of ESC and MSC is well characterized.10–12 In these
stem cell populations, incubation with VEGF at concentra-
tions of 50 ng/mL or higher has been shown to trigger pro-
duction of proteins constitutively expressed in endothelial
cells, such as von Willebrand factor (vWF),12–15 endothelial
nitric oxide synthase (eNOS),14,15 PECAM-1/CD31,14,16,17
vascular endothelial cadherin (VE-cadherin),12,14,16 and
VEGF receptor 2 (VEGFR2/KDR/Flk-1)12,16 and acquisition
of functional markers characteristic of endothelial cells, such
as uptake of acetylated low density lipoproteins (ac-LDL)16,17
and network formation when plated on Matrigel.12,14–16
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While several groups have reported that AFSC exposure to
similar VEGF concentrations results in certain endothelial
phenotypes,18,19 the functionality of endothelial cells differ-
entiated from human AFSC compared to a primary mature
cell source, such as human umbilical vein endothelial cells
(HUVEC), has yet to be thoroughly documented.
To determine whether AFSC were capable of differentiation
into functional endothelial cells, we cultured c-kit+ human
AFSC in an endothelial growth medium with supplemental
VEGF. We then quantified expression of the endothelial spe-
cific proteins vWF, eNOS, CD31, VE-cadherin, and VEGFR2,
assessed morphological changes, evaluated the loss of stem
cell specific markers postdifferentiation, and evaluated cell
function through network formation, acetylated-LDL uptake,
VEGF basal levels, and nitric oxide production.
Materials and Methods
Isolation of human AFSC
Primary human AF was obtained from patients in their
second trimester undergoing planned amnioreduction as
part of a therapeutic treatment for twin-twin transfusion
syndrome (TTTS). Collection from TTTS cases provides at
least an eightfold increase in AF per patient compared with
routine amniocentesis while maintaining a cell population
with a normal karyotype. The experimental protocol and
informed consent forms were approved by the Institutional
Review Boards of Baylor College of Medicine and Rice Uni-
versity. Isolation of AFSC was modified based on previously
published studies.1,8,20 AF was centrifuged at 1200 rpm for
10min, and collected cells were plated at 2500 cells/cm2 on
standard plastic Petri dishes and cultured in a modified
a-Minimum Essential Media: 63% aMEM (Invitrogen, Carlsbad,
CA), 18% Chang Basal Medium (Irvine Scientific, Santa Ana,
CA), 2% Chang C supplement (Irvine Scientific), 15% fetal
bovine serum (PAA Laboratories, Dartmouth, MA), and
GlutaMAX (Invitrogen) at 37C and 5% CO2 in a humidified
environment. Media was changed every 2–3 days, and cells
were passaged at 60%–70% confluence. At the first passage, a
subpopulation of progenitor cells was isolated through
fluorescence-activated cell sorting for expression of the mem-
brane receptor CD117/c-kit (BD Biosciences, Bedford, MA).
Cell colonies were detached into single cells (Accutase;
Sigma-ALdrich, St. Louis, MO; 37C, 10min), and c-kit+ cells
were collected using a Dako MoFlo sterile cell sorter.
Analysis of undifferentiated, C-kit + AF Cells
Standard G-banding karyotyping was performed on un-
differentiated AFSC at passage 5. Additionally, flow cy-
tometry using a BD LSR II Flow Cyotmeter was performed to
evaluate the expression of the embryonic stem cell marker
SSEA4, hematopoietic stem cell marker c-kit, mesenchymal
stem cell markers CD29, CD44, CD73, CD90, and CD105,
endothelial marker CD31, and hematopoietic differentiation
marker CD45. All flow cytometry antibodies and corre-
sponding isotype controls were purchased from BD Bio-
sciences, specific to human proteins, and used at manufacturer
recommended concentrations. FACSDiva software (BD Bio-
sciences) was used for all flow cytometry data collection.
FlowJo software (Tree Star, Inc., Ashland, OR) was used for
data analysis.
Endothelial differentiation of AFSC
C-kit + AFSC at passage 4 were plated on gelatin coated 12-
wellplatesatadensityof3000cells/cm2, allowed toattach for24h
in the modified aMEM, then cultured in Endothelial Growth
Media 2 (EGM-2; Lonza, Walkersville, MD) with a total concen-
tration of either 1, 5, 10, 25, 50, or 100ng/mL VEGF (VEGF165,
Pierce Biotechnology, Rockford, IL). EGM-2 contained epidermal
growth factor, hydrocortisone, GA-1000 (gentamicin, amphoter-
icin-b), fetal bovine serum, basic fibroblast growth factor, insulin-
like growth factor, ascorbic acid, and heparin at manufacturer
concentrations. All VEGF concentrations are final concentrations
and not in addition to the 2ng/mL supplied by Lonza.
Media was changed every 2–3 days, and the degree of
differentiation was assessed after 14 days. HUVEC (courtesy
of Nancy Turner, Rice University) cultured in EGM-2 with-
out supplemental VEGF were used as a positive control
while c-kit + AFSC in modified aMEM were used as a neg-
ative control. Both controls were analyzed at passage 4.
Immunostaining
To observe the presence and localization of endothelial-like
cells, the differentiated AFSC population was fixed with 4%
paraformaldehyde (Alfa Aesar,WardHill,MA), permeabilized
with Triton · 100 (CalBioChem, San Diego, CA), blocked with
1% bovine serum albumin (BSA; EMD Chemicals, Gibbstown,
NJ) for 1 hr at 25C, and stainedwith antibodies against human
vWF, (V8ProteaseFragment II;QEDBioscience Inc., SanDiego,
CA), eNOS (Abcam Inc., Cambridge, MA), VEGF receptor 2
(VEGFR2, Sigma-Aldrich), and VE-cadherin (BD Bioscience).
Primary antibodies were used at a concentration of 1:100
overnight at 4C, with secondary antibodies ( Jackson Im-
munoResearch Laboratories, Inc., West Grove, PA) diluted to
1:800 used for 30min at 25C. Cells were then counterstained
with 4¢,6-diamidino-2-phenylindole (DAPI) with Vecta Shield
(Vector, Burlingame, CA). Undifferentiated AFSC and differ-
entiated AFSC incubated with secondary antibodies alone
served as negative controls, while HUVEC served as positive
controls. Images were obtained using a DMI 6000B (Lieca
Microsystems, Bannockburn, IL) fluorescence microscope.
Morphology
ImageJ was used to process phase contrast images
through thresholding and calculate the circularity index,
computed as 4p*area/(perimeter)2, of each in-frame cell.
Postdifferentiation flow cytometry
Using the flow cytometry protocol and equipment previ-
ously described, differentiated AFSC were detached into sin-
gle cells and stained with fluorescently conjugated antibodies.
Targets and their respective isotype controls were as follows:
CD31 (FITC IgG1k), VE-cadherin (PE IgG1k), VEGFR2 (AF647
IgG1), SSEA4 (PE IgG3k), c-kit (PE IgG1k). All flow cytometry
antibodies and corresponding isotype controls were pur-
chased from BD Biosciences, specific to human proteins, and
used at manufacturer recommended concentrations.
Western blotting
Western blot antibodies were purchased from Abcam Inc.,
electrophoresis and transfer materials were purchased from
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Bio-Rad (Hercules, CA), and developing materials were
purchased from Thermo Scientific. After 14 days of dif-
ferentiation, total protein lysates were isolated from AFSC
and analyzed using a bicinchoninic acid kit (BCA; Thermo
Scientific, Rockford, IL). Extracts were denatured using b-
mercaptoethanol and boiling for 5min, then diluted to equal
concentrations of total protein. The samples were electro-
phoresed by 0.1% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and blotted onto nitrocellulose mem-
branes at 100 V for 1.5 and 1.0 h, respectively. Membranes
were washed in tris-buffered saline with 0.05% Tween-20
(TBST), then blocked with 5% nonfat milk in TBST to re-
duced nonspecific binding. Membranes were incubated
overnight at 4C with rabbit polyclonal antibodies against
eNOS (1:300 dilution in TBST) and mouse monoclonal anti-
bodies against glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (1:1000 dilution in TBST). Membranes were
washed and incubated for 30min at 25C with secondary
antibodies conjugated to horseradish peroxidase (HRP) at a
dilution of 1:1000. A 1min Luminol reagent exposure was
used to provide chemiluminescence, and images were de-
veloped using high-sensitivity x-ray film. Western blots were
normalized to GAPDH expression. Western blot analyze
was performed using Image J (NIH, Bethesda, MD).
Functional analysis of differentiated AFSC
Network formation on Matrigel. The potential for differ-
entiated AFSC to form networks was assessed using Growth
Factor Reduced Matrigel Matrix (BD Biosciences) according
to the manufacturer’s instructions. Briefly, Matrigel was al-
lowed to thaw on ice overnight, and then added to culture
plates at a concentration of 50mL/cm2. The coated plates
were then incubated at 37C for at least 30min to allow for
solidification. AFSC cultured for 14 days in EGM-2 supple-
mented with VEGF were dissociated with trypsin (Thermo
Scientific), replated at 7500 cells/cm2 on the Matrigel sub-
strate, and incubated at 37C for 24 h. Network formation
was assessed using standard light microscopy and the per-
centage of cells connected was determined by thresholding
using ImageJ, then manually counting cells that were con-
stituents of networks. In all functional assays, samples were
compared to undifferentiated AFSC and HUVEC under the
same protocols.
Ac-LDL uptake. Endothelial function was measured in
terms of uptake of acetylated low density lipoprotein (ac-
LDL). AFSC cultured for 14 days in EGM-2 supplemented
with VEGF were incubated with 10 mg/mL Alexa Fluor 488
conjugated ac-LDL (Invitrogen) for 4 h, then fixed with 4%
paraformaldehyde and counterstained with DAPI. For sta-
tistical analysis, in-frame cells were manually scored in terms
of degree of metabolized ac-LDL and categorized as either
negligible fluorescence, marginal to moderate fluorescence,
or strong fluorescence (similar to HUVEC). The percentage of
cells in each category was averaged across multiple frames,
and then compared by cell type.
VEGF production. Basal levels of VEGF production were
assessed using a human VEGF-specific enzyme-linked im-
munosorbent assay (Quantikine kit, R&D Systems, Inc.,
Minneapolis, MN). Cells were rinsed and incubated in EGM-
2 without supplemental VEGF for 48 h. According to man-
ufacturer protocols, cell culture supernatants were collected
and centrifuged, then incubated with HRP-conjugated anti-
body against VEGF for 2 h. A substrate solution was added
to the wells and color developed in proportion to the amount
of bound VEGF. The optical density of each well was de-
termined at 450 nm, with a correction wavelength of 540 nm,
using an Infinite M1000 PRO microplate reader (Tecan,
Ma¨nnedorf, Switzerland).
Nitric oxide production. The Measure-iT High-Sensitivity
Nitrite Assay Kit (Invitrogen) was used according to manu-
facturer recommendations to provide a surrogate for detec-
tion of nitric oxide. Briefly, the total byproduct of nitric
oxide was measured in the form of nitrites after conversion
of nitrates via nitrate reductase. Total nitrite levels for dif-
ferentiated AFSC were calculated based on a nitrite calibra-
tion curve, then normalized to total protein levels for each
sample.
Statistical analysis
Data are expressed as mean– standard deviation. The
sample numbers for each experiment are represented in their
respective figures. Analysis of variance analysis followed by
a post-hoc student t-test with a Dunn–Bonferroni correction
for multiple comparisons was performed for all comparisons.
A value of p< 0.05 was considered significant in all tests.
Results
Isolation and characterization of AFSC
Adherent AFSC were successfully isolated from 100mL
samples of AF and had a fibroblast-like, spindle-shaped
morphology similar to that of MSC (Fig. 1A). Standard
G-banding karyotyping revealed a normal diploid male
karyotype in 18/20 metaphase spreads. The remaining 2
spreads showed a tetraploid karyotype (Fig. 1B).
Flow cytometry on undifferentiated AFSC, sorted for
c-kit + at passage 2 and then cultured through passage 5,
showed the cells were strongly positive for the ESC marker
SSEA4, MSC markers CD29, CD44, CD73, CD90, and CD105,
and the immunological marker HLA-ABC, while a subpop-
ulation (25.5%) of these cells expressed c-kit. Additionally,
AFSC were negative for the immunological marker HLA-
DR, the hematopoietic differentiation marker CD45, and the
endothelial marker PECAM-1/CD31 (Fig. 1C). These results
are comparable to those of other groups.1,2,18,19
Differentiation of AFSC into endothelial-like cells
Differentiation of AFSC into endothelial-like cells (AFSC-
EC) was induced by incubating AFSC in the presence of
VEGF concentrations of 1, 5, 10, 25, 50, or 100 ng/mL. Im-
munofluorescence showed protein staining and localization
characteristic of endothelial cells. Undifferentiated AFSC
showed no specific staining for vWF, eNOS, VEGRF2, or VE-
cadherin, while AFSC after incubation in 50 ng/mL VEGF
for 2 weeks had significantly enhanced expression of each of
these proteins (Fig. 2A, B). Staining localization in differen-
tiated AFSC was similar to that of HUVEC, though the
percentage of cells expressing these markers, and therefore
overall intensity, was reduced. Incubation of AFSC-EC with
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secondary antibodies alone resulted in negligible fluores-
cence (Fig. 2C).
Based on a circularity index between 0 and 1, AFSC-EC
morphology after 14 days was significantly different when
compared with undifferentiated AFSC (n= 10 frames;
0.61 – 0.08 vs 0.21 – 0.08, respectively; p< 0.001) and similar to
that of HUVEC (0.64 – 0.17) (Fig. 3A).
The ability to form interconnected networks was assessed
by plating undifferentiated AFSC, differentiated AFSC cul-
tured in 50 ng/mL VEGF, and HUVEC on Matrigel thin
films. Few undifferentiated AFSC showed network forma-
tion (n= 10 frames; 5.2% – 3.6%) and the vast majority of the
cells maintained a rounded morphology. After differentia-
tion, significantly more AFSC-EC formed networks
(72.6% – 6.8%; p< 0.001), though less than HUVEC controls
(94.5% – 4.3%; p < 0.001) (Fig. 3B).
Functional characterization was also performed by asses-
sing uptake of AF488-conjugated ac-LDL. Undifferentiated
AFSC showed little to no phagocytosis of ac-LDL (n = 10
frames; 0.02% – 0.04%), while AFSC after incubation in
50 ng/mL VEGF after 2 weeks showed a varying degree of
ac-LDL uptake. A majority of the total population of AFSC-
EC showed some degree of ac-LDL uptake (64.5% – 10.9%;
p < 0.001 vs AFSC), whereas a smaller, yet still significant
population (43.9%– 7.1%; p< 0.001 vs AFSC) showed similar
ac-LDL uptake patterns to those of the HUVEC positive
control (93.7 – 6.0)(Fig. 3C, D).
The levels of basal VEGF expression (pg/106 cells) over 48h
by AFSC-EC across all VEGF incubation concentrations (n= 5;
742– 28, 787– 58, 815–52, 836– 33, 828– 7, 796–51) was sig-
nificantly greater than undifferentiated AFSC (151–14;
p< 0.005 for all conditions) and significantly lower than HU-
VEC controls (1470–267; p< 0.005 for all conditions) (Fig. 3E).
Quantitative flow cytometry of CD31 expression compared
to VEGF concentration in culture conditions showed a positive
correlation. Undifferentiated AFSC had a minimal CD31 ex-
pressing cells (n= 5 with 5· 105 cells/run; 1.6%– 0.6%),
whereas AFSC-EC showed increased CD31 expression at
VEGF incubation concentrations of 1, 5, 10, 25, 50, and 100ng/
mL after 2 weeks (5.8%– 2.5%, 6.2%– 3.3%, 8.1%– 3.8%,
9.6%– 2.7%, 22.6%– 7.4%, 13.5%– 3.4%, respectively) (Fig.
4A, B). AFSC-EC incubated with 50ng/mL VEGF displayed
significantly increased CD31 expression compared with
AFSC ( p< 0.05), and decreased compared with HUVEC
(85.8%– 6.7%; p< 0.001 vs AFSC-EC). Similarly, the percentage
of VE-cadherin and VEGFR2 positive AFSC-EC at 50ng/mL
VEGF (n= 1 run with 5· 105 cells; 21.7% and 30.7%, respec-
tively), were higher than those of AFSC (0.9% and 1.2%) and
lower than those of HUVEC (38.3% and 99.6%) (Fig. 4C), and
a subpopulation of AFSC-EC that was triple positive for
CD31, VE-cadherin, and VEGFR2 expression were identified
(8.9% of total population) (Fig. 4D). AFSC-EC also showed a
decrease in expression of the stem cell markers c-kit and
SSEA4 compared with undifferentiated AFSC (0.3% and
35.0%, respectively, down from 25.5% and 74.2%) (Fig. 4E).
ENOS expression in AFSC-EC at 50ng/mL VEGF was
significantly greater than in undifferentiated AFSC controls
(n= 5; fluorescence intensities of 3000– 320 and 157– 61, re-
spectively, normalize to GAPDH; p< 0.001), although signifi-
cantly less than HUVEC controls (3870– 130; p< 0.05). The
expression of eNOS significantly correlates with VEGF con-
centration (Fig. 5A, B). Note also the double-banding pattern
present in HUVEC controls and AFSC-EC (*130kDa and
110kDa). This pattern has been previously observed in other
studies21,22 and possibly results from alternative splicing or
degradation. Correspondingly, eNOS activity of AFSC-EC at
FIG. 1. Characterization of undifferentiated AFSC. AFSC were sorted for c-kit + cells at passage 2, cultured to passage 5, and
analyzed. (A) Light microscopy reveals a spindle-shaped morphology similar to MSC. Scale bar is 100 mm. (B) Standard G-
banding karyotyping of AFSC shows a normal diploid male karyotype. (C) FACS analysis reveals expression of immuno-
logical marker HLA-ABC, but not HLA-DR, expression of embryonic and mesenchymal stem cell markers SSEA4, c-kit,
CD29, CD44, CD73, CD90, and CD105, and no significant expression of endothelial and hematopoietic differentiation
markers. AFSC, amniotic fluid-derived stem cells; MSC, mesenchymal stem cells; FACS, fluorescence activated cell sorting.
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50ng/mL VEGF, analyzed through measurement of nitrite
levels normalized to total protein concentration, was signifi-
cantly greater than in undifferentiated AFSC controls
(17.33– 1.44 vs 9.88– 0.82 nmol/mg; p< 001), and significantly
less than HUVEC controls (19.81– 1.25 nmol/mg; p< 0.05)
(Fig. 5C). Agreement between eNOS production, the forma-
tion of nitric oxide, and CD31 expression confirms a cor-
relation between VEGF concentration and acquisition of
endothelial-like properties by differentiated AFSC.
Discussion
Broad potential for differentiation, a high rate of prolifer-
ation, and the ease of isolation make AFSC well suited for
FIG. 2. Protein localization within AFSC-derived endothelial cells. (A) Immunostaining for von Willebrand factor (green)
and endothelial nitric oxide synthase (red) and (B) VEGFR2 (green) and VE-cadherin (red) in (from top to bottom) undif-
ferentiated AFSC, AFSC-EC after 2 weeks of culture at 50 ng/mL VEGF, and HUVEC controls. (C) Images taken of AFSC-EC
at identical exposures without primary antibodies, as negative controls. Nuclei counterstained with DAPI (blue), overlap
shown at right. Scale bars are 100 mm. AFSC-EC, AFSC-derived endothelial cells; VEGF, vascular endothelial growth factor;
HUVEC, human umbilical vein endothelial cells; DAPI, 4¢,6-diamidino-2-phenylindole; VE-Cadherin, vascular endothelial
cadherin; VEGFR2, vascular endothelial growth factor receptor 2. Color images available online at www.liebertonline.com/tea
ENDOTHELIAL DIFFERENTIATION OF AFSC 1127
FIG. 3. Functional analysis of AFSC-de-
rived endothelial cells. (A) Morphological
analysis of AFSC, AFSC-EC differentiated at
50 ng/mL VEGF for 14 days, and HUVEC
based on a circularity index between 0 and 1
(n = 10 frames; 0.21 – 0.08, 0.61 – 0.08,
0.64 – 0.17, respectively). *p< 0.001 compared
with AFSC. Scale bars are 100mm. (B) As-
sessment of network formation by AFSC,
AFSC-EC, and HUVEC on Matrigel (n= 10
frames; 5.2% – 3.6%, 72.6% – 6.8%,
94.5% – 4.3%, respectively; *p< 0.001 vs
AFSC, #p < 0.001 vs AFSC-EC). Confocal
fluorescence imaging of phalloidin (green)
counterstained with DAPI (blue). Scale bars
are 200mm. (C, D) Fluorescence imaging of
acetylated low-density lipoprotein (green)
and percentage of AFSC, AFSC-EC, and
HUVEC metabolizing ac-LDL (n = 10 frames;
0.02% – 0.04%, 66.5% – 11.4%, 93.7 – 6.0, re-
spectively; *p< 0.001 vs AFSC, #p< 0.001 vs
AFSC-EC). Nuclei counterstained with DAPI
(blue), overlap at right. Scale bars are 50 mm.
(E) Basal VEGF expression (pg/106 cells)
over 48 h by AFSC (n = 5; 151 – 14), AFSC-EC
across all VEGF incubation concentrations
(742 – 28, 787– 58, 815 – 52, 836– 33, 828 – 7,
796 – 51), and HUVEC (1470 – 267). *p < 0.005
compared with AFSC-EC across all concen-
trations. Error bars are– SD. Color images
available online at www.liebertonline.com/
tea
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use in autologous or allogeneic regenerative medicine ther-
apies.23–25 This study illustrates the capability of c-kit + AFSC
to differentiate into endothelial-like cells on both the protein
expression and cell function levels. Growth factor induced-
differentiation of AFSC was augmented by supplementation
of VEGF in EGM-2, and a plateau in the acquisition of en-
dothelial-like characteristics was determined to occur be-
tween 25 and 50 ng/mL VEGF over the course of 2 weeks.
These findings are consistent with recent literature that has
examined VEGF-induced differentiation of embryonic and
MSC.10–15
Several distinct subpopulations of AF-derived cells express
mulitpotency markers, but c-kit+ AFSC have been consis-
tently shown to have the potential to differentiate into endo-
thelial-like cells.1,2,7 This immunoselection method is effective
at deriving stem cell-like AFSC from the initial heterogeneous
cell population. However, this technique is limited in its
clinical application due to the use of xenogenic antibodies.
While the method used in this paper is appropriate for the
current investigation, isolation without xeno-immunogenic
substances would be necessary to make differentiated cells
safe for human use.26 C-kit+ endothelial progenitor cells such
as these could be utilized for the development of engineered
blood vessels, vascularization of engineered tissues, and pro-
motion of vessel growth in ischemic tissue.
Previous studies have observed endothelial differentiation
of AFSC when cells were cultured in EGM-2 supplement
with 2 ng/mL recombinant human basic fibroblast growth
factor for 8 days, as determined by CD31 expression alone, or
either 10 or 50 ng/mL VEGF for 14 days, with results
quantified by combined CD31 and vWF expression.18–20
Although the molecular mechanisms responsible for vascu-
logenesis and angiogenesis are currently not fully under-
stood, the importance of the VEGF signaling pathway for
both processes is evident.27 Therefore, VEGF is often used as
the primary stimulus for chemical-mediated differentiation
of AF-derived, mesenchymal, and ESC into endothelial cells
in vitro. Additionally, the effect of shear force and hypoxia on
the stimulation of vWF, eNOS, and VEGF production has
been examined in ESC, MSC, and AFSC.20,28,29 Across these
studies, including our own, endothelial marker expression
was seen as early as 1 week, though expression was signif-
icantly increased within the second week of VEGF exposure.
The enzyme eNOS plays an essential role downstream of
VEGF signaling pathway, stimulating migration, prolifera-
tion, and vasodilation in vivo through nitric oxide produc-
tion. Genetic upregulation of eNOS has been shown to
increase VEGF-dependent neovascularization, suggesting
eNOS expression in our differentiated cells can further pro-
mote the endothelial phenotype.30
FIG. 4. Flow cytometry analysis of AFSC-derived endothelial cells. (A, B)CD31 expression in AFSC, AFSC-EC across all VEGF
concentrations, and HUVEC shown as percentage increase versus isotype controls (n= 5 with 5· 105 cells/run; 1.6%– 0.6%;
5.8%– 2.5%, 6.2%– 3.3%, 8.1%– 3.8%, 9.6%– 2.7%, 22.6%– 7.4%, 13.5%– 3.4%; 85.8%– 6.7%; *p< 0.05 vsAFSC, #p< 0.001 vsAFSC-
EC). (C) VE-cadherin and VEGFR2 expression in AFSC-EC at 50ng/mL VEGF (n= 1 run with 5· 105 cells; 21.7% and 30.7%,
respectively) and HUVEC (38.3% and 99.6%). (D) Subpopulation of AFSC-EC at 50ng/mL VEGF triple positive for CD31, VE-
cadherin, and VEGFR2 expression (8.94% of total population). (E) Reduced expression of stem cell markers c-kit and SSEA4
postdifferentiation in AFSC-EC (0.3% and 35.0%, respectively). Error bars are–SD. CD31, cluster of differentiation 31.
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When AFSC were cultured in media without VEGF, im-
munofluorescent staining did not reveal vWF, eNOS, VE-
cadhern, or VEGFR2 expressions, which are all constitutively
expressed in mature endothelial cells. However, significant
expression of these markers was present with the addition of
VEGF at 50 ng/mL to EGM-2 for 2 weeks, and localization of
vWF in Weibel-Palade bodies, and eNOS, VE-cadherinin,
and VEGFR2 in cell membranes was observed in these
samples. Incubation of differentiated AFSC in secondary
antibodies alone did not reveal significant fluorescence,
confirming the specificity of the primary antibodies used.
Analysis using Western blotting revealed increased expres-
sion of eNOS as a function of VEGF concentrations ranging
from 1 to 50 ng/mL with no significant increase in marker
expression at higher concentrations. To our knowledge, this
study shows for the first time that AFSC-EC are capable of
producing functional eNOS, as determined by nitric oxide
production, at physiologically relevant concentrations.
Further examination revealed that CD31 expression by
AFSC-EC was also dependent on VEGF. Over a range of
VEGF concentrations from 1–100 ng/mL, 50 ng/mL resulted
in maximal expressions of eNOS and CD31 expression, with
little to no added acquisition of endothelial properties at
higher VEGF concentrations. In some cases, concentrations of
VEGF as high as 100 ng/mL had the potential for reduced
efficacy, as shown in this study through CD31 expres-
sion and prior studies with ESC.11 Additionally, the basal
level of VEGF production by AFSC-EC across all VEGF
concentrations was negligible compared with supplemental
concentrations. At the optimal VEGF concentration, post-
differentiation analysis showed a decrease in the stem cell
markers SSEA4 and c-kit and the presence of a subpopula-
tion of AFSC-EC that were triple positive for CD31, VE-
cadherin, and VEGFR2, which supports the hypothesis of
endothelial differentiation.
AFSC-EC were morphologically similar to HUEVC and, in
addition to nitric oxide production, displayed other func-
tional characteristics of fully mature endothelial cells. Vas-
culogenic potential of these cells was shown by assessing the
formation of networks when plated on a semi-solid sub-
strate, and internalization of ac-LDL distinctly identified
endothelial cells based on metabolic activity. The primary
advantages of using ac-LDL metabolism as a marker are that
it allows for labeling of live endothelial cells without the
need for fixation or permeabilization to optimize staining,
does not affect cell viability, and is not removed during
trypsinization due to incorporation into lysosomal mem-
branes; therefore, the use of fluorescently labeled ac-LDL will
allow for isolation of AFSC-EC from the undifferentiated
AFSC population.
AFSC isolated through adherence and c-kit + im-
munoselection, then exposed to 50 ng/mL VEGF for 14 days,
express key endothelial molecular markers (vWF, eNOS,
CD31, VE-cadherin, and VEGFR2), were morphologically
similar to HUVEC, and display functional phenotypes as-
sociated with endothelial cells (nitric oxide production, net-
work formation, and ac-LDL uptake). These results suggest
that AFSC are able to differentiate into functional endothelial
cells in vitro and are suited for evaluation for vasculogenic
potential within a tissue-engineered construct in vivo.
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